Cloud DX has been awarded $1.75 million in Supercluster funding from NGen, Canada’s Advanced Manufacturing Supercluster, to develop Pulsewave 2.0, a solution to remotely monitor patients sent home from the hospital, including those vulnerable to or exposed to COVID-19.
The Cloud DX Connected Health platform gives doctors the automated monitoring ability to send many non-acute patients home sooner, freeing up beds and relieving pressure on front line staff. Pulsewave 2.0 is the next iteration of Cloud DX’s blood pressure monitor.
This Bluetooth-enabled wrist cuff records and analyses a patient’s radial artery pulse and delivers average breathing rate, average heart rate and blood pressure measurements. The Connected Health platform consists of a mobile application for patients, clinician dashboards, smart software that automates the gathering of vital signs, patient symptom surveys, video and text message capabilities and customised healthcare content. Cloud DX services allows doctors and nurses to set notification triggers that can alert them when a patient’s vital signs or symptoms change.
NGen funding will help fast-track regulatory approval and transition to manufacturing of the Pulsewave 2.0 and enable Cloud DX to begin manufacturing vital sign monitors at scale, in Canada.
Once this manufacturing centre is fully operational, Cloud DX plans to expand its product line with additional devices currently under development, including the wearable Vitaliti continuous vital sign monitor.
